Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662825 · ClinicalTrials.gov registry record
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 376
- Enrollment target
NCT06662825: Completed study, sponsored by Novartis.
NCT06662825 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 376 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06662825 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 376 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Primary Outcome
Index date was defined as the date of the first crizanlizumab infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2023-11-01 |
What the finished NCT06662825 record still lists
NCT06662825 is an observational study that tracks outcomes without assigning an intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06662825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06662825 about?
NCT06662825 is a clinical study titled "Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers". This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
What is the current status of trial NCT06662825?
This trial is currently completed. The enrollment target is 376 participants. The study started on 2022-12-13. Estimated completion is 2023-11-01.
Who is sponsoring clinical trial NCT06662825?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI